Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus

Diabetes, Obesity and Metabolism

Volumn 13, Issue 4, 2011, Pages 357-365

  Kasichayanula, S ^a   Chang, M ^a   Hasegawa, M ^a   Liu, X ^a   Yamahira, N ^a   LaCreta, F P ^a   Imai, Y ^a   Boulton, D W ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Antidiabetic drug; Clinical trial; Japanese; Pharmacodynamics; Pharmacokinetics; SGLT2 inhibitor; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; DAPAGLIFLOZIN; DAPAGLIFLOZIN 3 O GLUCURONIDE; GLUCOSE; SODIUM GLUCOSE COTRANSPORTER 2; UNCLASSIFIED DRUG;

ADULT; ADVERSE DRUG REACTION; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SINGLE DRUG DOSE;

EID: 79951897566     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2011.01359.x     Document Type: Article

References (16)

1. IDF Diabetes Atlas. International Diabetes Federation. Diabetes and impaired glucose tolerance. Global burden: prevalence and projections, 2010 and 2030. 2010.
2. World Health Organization. Diabetes. World Health Organization 4-3-2010.
3. Ministry of Health, Labour and Welfare National Nutrition Survey. Diabetes Fact Book. Ministry of Health 2010.
4. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the study of diabetes. Diabetes Care 2009; 32: 193-203.
5. Marsenic O. Glucose control by the kidney: an emerging target in diabetes. Am J Kidney Dis 2009; 53: 875-883.
6. Bakris GL, Fonseca VA, Sharma K et al. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int 2009; 75: 1272-1277.
7. Han S, Hagan DL, Taylor JR et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008; 57: 1723-1729.
8. Meng W, Ellsworth BA, Nirschl AA et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2008; 51: 1145-1149.
9. Ferrannini E, Ramos SJ, Salsali A et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Care 2010; 33: 2217-2224.
10. List JF, Woo V, Morales E et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009; 32: 650-657.
11. Bailey CJ, Gross JL, Pieters A et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375: 2223-2233.
12. Wilding JPH, Norwood P, T'joen C et al. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers. Applicability of a novel insulin-independent treatment. Diabetes Care 2009; 32: 1656-1662.
13. Komoroski B, Vachharajani N, Feng Y et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2009; 85: 513-519.
14. Komoroski B, Vachharajani N, Boulton D et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 2009; 85: 520-526.
15. Obermeier M, Yao M, Khanna A et al. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab Dispos 2010; 38: 405-414.
16. Feng Y, Zhang L, Komoroski B, Pfister M. Population pharmacokinetic analysis of dapagliflozin in healthy subjects and patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2010; 83: S93.